Advertisement

Topics

Clinical Trials About "Respected Valley Stream Office Ophthalmic Consultants Long Island" RSS

02:43 EDT 23rd March 2019 | BioPortfolio

We list hundreds of Clinical Trials about "Respected Valley Stream Office Ophthalmic Consultants Long Island" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Respected Valley Stream Office Ophthalmic Consultants Long Island" on BioPortfolio

We have published hundreds of Respected Valley Stream Office Ophthalmic Consultants Long Island news stories on BioPortfolio along with dozens of Respected Valley Stream Office Ophthalmic Consultants Long Island Clinical Trials and PubMed Articles about Respected Valley Stream Office Ophthalmic Consultants Long Island for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Respected Valley Stream Office Ophthalmic Consultants Long Island Companies in our database. You can also find out about relevant Respected Valley Stream Office Ophthalmic Consultants Long Island Drugs and Medications on this site too.

Showing "Respected Valley Stream Office Ophthalmic Consultants Long Island" Clinical Trials 1–25 of 10,000+

Relevant

Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features

The primary purpose of the study is to determine if Seneca Valley Virus may be administered safely to patients with certain types of advanced cancer.


A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study

The purposes of this study are to evaluate the long-term safety and intraocular pressure-lowering efficacy of DE-117 ophthalmic solution monotherapy and concomitant use of DE-117 ophthalmic solution with timolol ophthalmic solution 0.5% in patients with open angle glaucoma or ocular hypertension.

Rift Valley Fever in Kenya

The purpose of this study is to find out how, why, and when Rift Valley Fever (RVF) spreads. Participants will be 250 adults and children, aged 1 year and older, from the Ijara District, Kenya. They will be given a questionnaire, undergo a medical examination that includes an eye exam, and have a 1-teaspoon sample of blood taken from a vein. Participation will take about 3 hours.


Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

The purpose of this study is to evaluate if DE-101 ophthalmic suspension will safely and effectively improve signs and or symptoms of dry eye disease.

A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-

The purposes of this study are to determine the optimal concentration of DE-117 ophthalmic solution compared to the placebo ophthalmic solution and to determine if intraocular pressure reduction after 4 weeks of treatment with DE-117 ophthalmic solution is non-inferior to latanoprost ophthalmic solution 0.005%.

A Randomized, Double Masked, Clinical Study to Assess ADX-102 Ophthalmic Solution in Subjects With Dry Eye Syndrome

The objective of this study is to evaluate the safety, tolerability, and pharmacodynamic activity of ADX-102 Ophthalmic Solutions and ADX-102 Ophthalmic Lipid Solution in subjects with dry eye syndrome.

Long Term Administration Study of OPC-12759 Ophthalmic Suspension

The purpose of this study is to evaluate safety and efficacy of OPC-12759 ophthalmic suspension during 52 weeks in dry eye patients

Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome

The objective of this study is to identify the concentration and daily dosing frequency of BOL-303242-X ophthalmic suspension in treating dry eye syndrome over a 12 week dosing period.

A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

Safety and efficacy of DE-114 ophthalmic solution will be evaluated in patients with allergic conjunctivitis, in an open-label, multicenter study.

Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine

This study is to determine if a vaccine for Rift Valley Fever (RVF) is safe to give to humans. Rift Valley Fever is a disease carried by mosquitoes that can infect both animals and humans. The study will also examine how well the vaccine (RVF MP-12) stimulates the body's immune response (which fights off infection) and if the vaccine is stable or if the virus used to make the vaccine changes into a different form once injected into the body. Twenty healthy volunteers (18-50 yea...

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

This study will evaluate the long-term safety of bimatoprost 0.01% ophthalmic solution compared with bimatoprost 0.03% ophthalmic solution in patients with glaucoma or ocular hypertension.

Practice of "Chemical Sex" by HIV Patients in Reunion Island

The term "CHEMSEX", short for "chemicals" and "sex", is used to define the consumption, regardless of the route of administration, of drugs or substances for recreational use, in a sexual context. No published data is currently available concerning this practice in Reunion Island. However, an upsurge in cases of acute hepatitis C was observed at the end of 2016 (4 in 6 months) of which 3 were related to the practice of chemsex (data CeGGID Réunion) and the recent years ...

Study on Seroprevalence and Risk Factors of Coxiella Burnetii (Q Fever) in the South of Reunion Island

Emergent and infectious diseases are a public health priority on Reunion Island. Amongst public health threats, the infection due to Coxiella burnetii (Q fever) seems to have appeared on Reunion island in 2007 with two hospitalised confirmed cases (one death) and one probable case with a goat farmer. According to the investigator, the diffusion of C. burnetti is more ancient and such diagnosis have been made in the last 30 years with 80 positive serologies identified between ...

DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%

DE-111 ophthalmic solution will be evaluated for superiority in comparison with Tafluprost 0.0015% ophthalmic solution, or for non-inferiority in comparison with Tafluprost 0.0015% and Timolol ophthalmic solution 0.5% used concomitantly, in IOP-lowering effect in primary open-angle glaucoma or ocular hypertension patients, in a multicenter, randomized, double-masked, parallel-group comparison study. Safety will be compared and evaluated as well.

A Study of AL3583 Ophthalmic Solution 0.05%, 0.010% Versus AL38583 Vehicle for Dry Eye

The purpose of this study is to determine whether AL38583 Ophthalmic solution is effective for treatment of signs and symptoms of dry eye.

Study of INS115644 Ophthalmic Solution in Subjects With Ocular Hypertension or Glaucoma

The purpose of this trial is to evaluate the safety and tolerability of INS115644 Ophthalmic Solution in subjects with bilateral ocular hypertension or early primary open angle glaucoma and to investigate the intraocular pressure lowering effects of INS115644 Ophthalmic Solution.

Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy

To explore efficacy and safety of 0.5 mg conbercept ophthalmic injection for long-term treatment of polypoid choroidal vasculopathy (PCV) subjects.

Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine

This study is to collect safety and immunogenicity data for an Rift Valley Fever (RVF) vaccine

Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated

This study is designed to determine the safety and immunogenicity of an inactivated Rift Valley Fever (RVF) Vaccine in adults

Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to netarsudil (AR-13324) ophthalmic solution 0.02% and latanoprost ophthalmic solution 0.005%

Cancer Survival in Reunion Island , 1998-2008 (SUCRE)

Cancer survival is important to determine prognostic of patients and evaluate care and prevention health strategies. Sucre is the first study to describe cancer survival in Reunion Island. Sucre aims at evaluating five year cancer prognostic in Reunion Island by cancer site and gender. Sucre is a retrospective cohort study of cancer diagnosed between 01/01/1998 and 31/12/2008.

A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model

To evaluate the efficacy of Bilastine ophthalmic solution 0.6% compared to vehicle and Zaditen (Ketotifen ophthalmic solution 0.025%) for the treatment of the signs and symptoms of allergic conjunctivitis.

Ocular Hypotensive Efficacy of AR-102

A double-masked, randomized, vehicle-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of AR-102 in subjects with elevated intraocular pressure. The Null hypothesis is that the ocular hypotensive efficacy of each dose of AR-102 Ophthalmic Solution will not be different from that of its vehicle.

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye.

Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan

The purpose of this study is to evaluate the effectiveness and safety of Olopatadine HCl ophthalmic solution 0.1% versus Epinastine HCl ophthalmic solution, 0.05% in a population of healthy, adult Japanese patients (20 years of age or older) with a history of allergic conjunctivitis to Japanese Cedar Pollen. Patients will be randomly assigned to receive Olopatadine HCl ophthalmic solution, 0.1% in one eye and Epinastine HCl ophthalmic solution, 0.05% in the fellow eye, after...


More From BioPortfolio on "Respected Valley Stream Office Ophthalmic Consultants Long Island"

Advertisement
Quick Search
Advertisement
Advertisement